Immuneering (IMRX) Return on Capital Employed (2021 - 2026)

Immuneering's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 27.12% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 11075.0% year-over-year to 27.12% in Q1 2026; TTM through Mar 2026 was 27.12%, a 11075.0% increase from a year earlier, with the FY2025 full-year figure at 44.89%, up 4645.0% from the prior year.
• Return on Capital Employed eased to 27.12% in Q1 2026 per IMRX's latest filing, from 26.22% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 26.03% in Q1 2022 and bottomed at 169.14% in Q2 2025.
• The 5-year median for Return on Capital Employed is 49.31% (2023), against an average of 65.46%.
• Across the five-year window, Return on Capital Employed tumbled 8932 bps in 2025 and surged 11075 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 43.13% in 2022, then tumbled by 35 bps to 58.19% in 2023, then plunged by 107 bps to 120.59% in 2024, then surged by 78 bps to 26.22% in 2025, then decreased by 3 bps to 27.12% in 2026.
• Per Business Quant, the three latest IMRX Return on Capital Employed figures stand at 27.12% (Q1 2026), 26.22% (Q4 2025), and 48.99% (Q3 2025).